Table 2.

Treatment exposure (safety population).

Total number of cycles administered (median), [range], [IQR]	1,079 (6) [Range, 1–31], [IQR 3–9]
Cycles with delayed schedule	33(3.1%)
Cycles with dose modification were made
Capecitabine	776 (71.9%)
Bevacizumab	10(0.9%)
Relative dose intensity, median (%), [range], [IQR]
Capecitabine (twice per day, mg/m2)	80.2% (1,003 mg/m2 [Range, 778.4–1282.1], [IQR 926.5–1227]
Bevacizumab (mg/kg)	100% (7.5 mg/kg) [Range, 5.0–7.5], [IQR 7.5–7.5]